Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates... see more

Recent & Breaking News (NDAQ:INCY)

Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease

Business Wire March 25, 2022

Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting

Business Wire March 18, 2022

Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura(TM)) for the Treatment of Vitiligo

Business Wire March 14, 2022

Incyte to Present at Upcoming Investor Conference

Business Wire February 15, 2022

Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs

Business Wire February 8, 2022

Incyte to Present at Upcoming Investor Conference

Business Wire February 3, 2022

Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis

PR Newswire January 28, 2022

Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

GlobeNewswire January 25, 2022

Incyte Provides Update on Parsaclisib and MCLA-145

Business Wire January 25, 2022

Incyte to Report Fourth Quarter and Year-End 2021 Financial Results

Business Wire January 18, 2022

Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura(TM)) as a Treatment for Patients with Vitiligo

Business Wire December 14, 2021

Incyte to Present at Upcoming Investor Conferences

Business Wire December 14, 2021

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Business Wire December 11, 2021

Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Business Wire December 11, 2021

OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis

PR Newswire November 9, 2021

Incyte to Present at Upcoming Investor Conference

Business Wire November 9, 2021

Cellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies

PR Newswire November 4, 2021

More than 35 Abstracts from Incyte's Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition

Business Wire November 4, 2021

Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Business Wire November 2, 2021

Data from Incyte's Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Business Wire November 1, 2021